Treament options in advanced castration-resistant, prostate cancer (acrpc). preliminary results of a network meta-analysis

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.

BACKGROUND Tranilast is a therapeutic agent used in treatment of allergic diseases. It has been reported previously that tranilast has antitumour effects on prostate cancer cells. This study examined whether tranilast has clinical benefit for prostate cancer patients. PATIENTS AND METHODS Twenty-one Japanese patients with advanced castration-resistant prostate cancer (CRPC) were administered ...

متن کامل

Single Orbital Metastasis in Castration-Resistant Prostate Cancer

Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...

متن کامل

Single Orbital Metastasis in Castration-Resistant Prostate Cancer

Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...

متن کامل

New treatment options in castration-resistant prostate cancer.

Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer agents in the mix. At the NCCN 20th Annual Conference, Dr. Andrew J. Armstrong discussed some of the key developments in metastatic castration-resistant and castration-sensitive prostate cancer, particularly the conflictin...

متن کامل

Castration-resistant Prostate CanCer

• Objective: To review therapeutics for castrationresistant prostate cancer (CRPC). • Methods: Literature review. • Results: Targeting of androgen-dependent pathways in CRPC post-chemotherapy has been shown to improve survival with the lyase inhibitor abiraterone and lead to PSA and objective responses with an androgen receptor antagonist (MDV3100). However, the addition of bevacizumab to docet...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of Oncology

سال: 2016

ISSN: 0923-7534

DOI: 10.1093/annonc/mdw334.26